THE RELATIONSHIP OF GUT MICROBIOTA AND OBESITY AND TREATMENT WITH SEMAGLUTIDE

• DOI: https://doi.org/10.22533/at.ed.1594642401077

• Palavras-chave: Obesity. Semaglutide. Treatment. Intestinal microbiota.

• Keywords: Obesity. Semaglutide. Treatment. Intestinal microbiota.

• Abstract:

  This article seeks to address obesity as a highly prevalent pathology, which causes a high degree of morbidity and mortality due to its complications and the illnesses that result from it. In this sense, the use of semaglutide and similar products is discussed, given that the Federal Drug Administration (FDA) and Anvisa have already admitted the registration of the aforementioned medication for weight control in adults, under medical indication, and the guidance for its use is always accompanied by a low-calorie diet and physical exercise. The release of this, as an adjuvant medication in the treatment of obesity, has its action on the intestinal microbiota, thus presenting its effectiveness and the relationship between the specific action of the medication and the results presented. The present study used a literary review that will seek to be based on scientific articles and other publications related to the topic covered. The sources will be accessed in recognized databases, such as Google Scholar and the Scielo Databases. To this end, publications from the last 10 years will be selected. As results of this study, the interaction between the intestinal microbiota and intrinsic obesity can be observed, and treatment with semaglutide has shown promising potential not only for weight loss, but above all for the modulation of the microbiota, bringing an integrated approach to treatment. of obesity.